Trials / Recruiting
RecruitingNCT04561492
Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma
Exploratory Study Evaluating the Relevance of [68Ga]Ga -PentixaFor for Initial Staging and Therapeutic Evaluation of Symptomatic Multiple Myeloma Patients in First Line Treatment or in Relapse
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of our study is to confirm the relevance of PET using \[68Ga\]Ga -PentixaFor ligand, in comparison with FDG, for initial staging and therapeutic evaluation of symptomatic multiple myeloma patients in first line treatment or in relapse. The prognostic value of positive CXCR4 expression will also be assessed and \[68Ga\]Ga -PentixaFor/FDG discordances explored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [68Ga]Ga-PentixaFor | Tomography by emission of positons (PET) with theradiopharmaceutic \[68Ga\]Ga-PentixaFor |
Timeline
- Start date
- 2021-09-21
- Primary completion
- 2029-12-21
- Completion
- 2030-05-21
- First posted
- 2020-09-23
- Last updated
- 2025-12-08
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04561492. Inclusion in this directory is not an endorsement.